The needle-free allergy rescue spray just won the vote that matters most: patients'

Data presented at the BSACI 2026 allergy meeting in Newport, Wales, by Danish pharma ALK found that in a UK study of 90 severe-allergy patients, caregivers and first-time users, the EURneffy nasal adrenaline spray was rated significantly less burdensome than EpiPen-style injectors on every patient-built measure — more compact, more convenient, more independence. In a Canadian study of 120 people, 94% called the spray intuitive against 58% for the injector. Roughly half of anaphylaxis patients don't carry or don't use their device in an emergency; a spray with no needle could change that.